Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $914
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an 'Overweight' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) but lowered the price target from $915 to $914.
November 03, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been lowered by Morgan Stanley from $915 to $914, while maintaining an 'Overweight' rating.
While the price target has been lowered, the 'Overweight' rating indicates that Morgan Stanley still sees potential in Regeneron Pharmaceuticals. However, the minor decrease in the price target could slightly impact investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100